GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Scaled Net Operating Assets

Neurizon Therapeutics (FRA:ECQ0) Scaled Net Operating Assets : 0.32 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Neurizon Therapeutics's operating assets for the quarter that ended in Dec. 2023 was €1.99 Mil. Neurizon Therapeutics's operating liabilities for the quarter that ended in Dec. 2023 was €0.75 Mil. Neurizon Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was €3.80 Mil. Therefore, Neurizon Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.32.


Neurizon Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Neurizon Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Scaled Net Operating Assets Chart

Neurizon Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 0.69 0.65 0.21 -0.08

Neurizon Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.64 0.22 0.33 -0.06

Competitive Comparison of Neurizon Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Neurizon Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurizon Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's Scaled Net Operating Assets falls into.



Neurizon Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Neurizon Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2023 )
=(Operating Assets (A: Jun. 2023 )-Operating Liabilities (A: Jun. 2023 ))/Total Assets (A: Jun. 2022 )
=(2.121-0.738)/6.7
=0.21

where

Operating Assets(A: Jun. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.797 - 1.676
=2.121

Operating Liabilities(A: Jun. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1.388 - 0.552 - 0.098
=0.738

Neurizon Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(1.987-0.753)/3.797
=0.32

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5.333 - 3.346
=1.987

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.753 - 0 - 0
=0.753

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurizon Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurizon Therapeutics Business Description

Traded in Other Exchanges
Address
96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines